Is Adherium Limited Strengthening Its Growth Plans After Securing AU$6.70 million in Fresh Capital?
Source: Kapitales Research
Highlights
• Adherium Limited (ASX: ADR) shares were trading at AU$0.005 at the time of writing, with no change during the session.
• The company secured AU$6.70 million at the time of writing through a Placement and Institutional Entitlement Offer priced at AU$0.003 per share.
• Funds will be directed toward accelerating Remote Patient Monitoring growth and expanding value-based care contracts in the United States at the time of writing.
Adherium Limited (ASX: ADR) was trading at AU$0.005 at the time of writing, reflecting no movement in its share price during the session. The steady performance follows the company’s confirmation that it has completed the Placement and institutional component of its Accelerated Pro-Rata Non-Renounceable Entitlement Offer, raising AU$6.70 million at the time of writing.
The capital raise comprises approximately AU$1.34 million from the Placement and around AU$5.37 million from the Institutional Entitlement Offer at the time of writing. The offer price was set at AU$0.003 per new share at the time of writing. Institutional shareholders took up approximately 66% of their entitlements, with any shortfall allocated to new and existing institutional investors.
The retail component of the Entitlement Offer is expected to open on 23 February 2026, with a target of up to AU$0.82 million at the time of writing. Proceeds will be used to support commercial initiatives, particularly to scale growth in the Remote Patient Monitoring channel and to advance the company’s expansion into value-based care contracts with U.S. insurers, as of the time of writing.
What Comes Next?
Management indicated that the fresh capital will support upcoming inflection points, including the release of final iCARE clinical study data and continued development of additional revenue channels in the United States. The funding strengthens the balance sheet as the company pursues broader commercialisation opportunities.
Single-Point Summary
Adherium’s unchanged share price at the time of writing comes as the company secures AU$6.70 million in new institutional funding to accelerate RPM expansion and U.S. value-based care growth.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Is Adherium Limited Strengthening Its Growth Plans After Securing AU$6.70 million in Fresh Capital?
Highlights
• Adherium Limited (ASX: ADR) shares were trading at AU$0.005 at the time of writing, with no change during the session.
• The company secured AU$6.70 million at the time of writing through a Placement and Institutional Entitlement Offer priced at AU$0.003 per share.
• Funds will be directed toward accelerating Remote Patient Monitoring growth and expanding value-based care contracts in the United States at the time of writing.
Adherium Limited (ASX: ADR) was trading at AU$0.005 at the time of writing, reflecting no movement in its share price during the session. The steady performance follows the company’s confirmation that it has completed the Placement and institutional component of its Accelerated Pro-Rata Non-Renounceable Entitlement Offer, raising AU$6.70 million at the time of writing.
The capital raise comprises approximately AU$1.34 million from the Placement and around AU$5.37 million from the Institutional Entitlement Offer at the time of writing. The offer price was set at AU$0.003 per new share at the time of writing. Institutional shareholders took up approximately 66% of their entitlements, with any shortfall allocated to new and existing institutional investors.
The retail component of the Entitlement Offer is expected to open on 23 February 2026, with a target of up to AU$0.82 million at the time of writing. Proceeds will be used to support commercial initiatives, particularly to scale growth in the Remote Patient Monitoring channel and to advance the company’s expansion into value-based care contracts with U.S. insurers, as of the time of writing.
What Comes Next?
Management indicated that the fresh capital will support upcoming inflection points, including the release of final iCARE clinical study data and continued development of additional revenue channels in the United States. The funding strengthens the balance sheet as the company pursues broader commercialisation opportunities.
Single-Point Summary
Adherium’s unchanged share price at the time of writing comes as the company secures AU$6.70 million in new institutional funding to accelerate RPM expansion and U.S. value-based care growth.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au